WO1996035785A2 - Transgenic animals having a defective thyroid hormone receptor beta gene - Google Patents

Transgenic animals having a defective thyroid hormone receptor beta gene Download PDF

Info

Publication number
WO1996035785A2
WO1996035785A2 PCT/EP1996/001983 EP9601983W WO9635785A2 WO 1996035785 A2 WO1996035785 A2 WO 1996035785A2 EP 9601983 W EP9601983 W EP 9601983W WO 9635785 A2 WO9635785 A2 WO 9635785A2
Authority
WO
WIPO (PCT)
Prior art keywords
gene
hormone receptor
thyroid hormone
mice
thrb
Prior art date
Application number
PCT/EP1996/001983
Other languages
French (fr)
Other versions
WO1996035785A3 (en
WO1996035785A9 (en
Inventor
Douglas Forrest
Thomas Curran
Original Assignee
Karo Bio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio Ab filed Critical Karo Bio Ab
Priority to AU59981/96A priority Critical patent/AU5998196A/en
Publication of WO1996035785A2 publication Critical patent/WO1996035785A2/en
Publication of WO1996035785A3 publication Critical patent/WO1996035785A3/en
Publication of WO1996035785A9 publication Critical patent/WO1996035785A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This application relates to transgenic animals, particularly mice, and tissues and cell lines
  • TR ⁇ thyroid hormone receptor ⁇
  • mice, tissues and cell lines of the invention may be used in the testing for pharmaceutical or clinical purposes of substances such as thyroid hormones T 3 and T 4 and possible antagonists
  • thyroid hormones tri-iodothyronine (T 3 ) and thyroxine (T 4 ) have a very wide range of effects. In adult mammals they influence nearly all organs, the metabolism of nutrients, basal metabolic rate and oxygen consumption. In humans, the deficiency or excess of circulating thyroid hormones results in the well characterised syndromes hypo- and hyperthyroidism.
  • the thyroid hormones are essential for the normal development of the central nervous system
  • hypothyroidism that can be due to either acquired or congenital disorders.
  • Some of the congenital causes of hypothyroidism are embryopathies as absence, hypoplasia,
  • GRTS Generalized Thyroid Hormone Syndrome
  • congenital hypothyroidism leads to irreversible mental retardation and short stature (dwarfism).
  • Other symptoms include neurological dysfunctions such as poor coordination and balance, abnormal fine motor movements, speech problems, spasticity, tremor and hyperactive
  • hypothyroidism In contrast to congenital hypothyroidism, hyperthyroidism is more common in adults. In general, the symptoms are the reverse: increased metabolism, lower serum cholesterol levels, hyperactivity and tachycardia are hallmarks of elevated T3/T4 levels 25 .
  • Thyroid hormones act through thyroid hormone receptors (TRs) which belong to the TRs
  • TRs are ligand dependent transcription factors which regulate the transcription of their target genes through responsive elements in the DNA.
  • TRs 7"13 derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety of TRs 7"13 (Fig. A) derived from TR ⁇ and TR ⁇ genes, which are a variety
  • the ⁇ -gene encodes the subtypes l and ⁇ 2.
  • the ⁇ 2 subtype is not a functional receptor in the sense that it lacks T 3 /T 4 hormone binding capability.
  • the ⁇ -gene encodes the subtypes ⁇ 1 and ⁇ 2. The latter has so far been identified only at the
  • TR ⁇ and Tr ⁇ 3 variants have been clarified. Different amino- and carboxy-termini for the TR variants suggest different trans-activating properties for TR ⁇ and Tr ⁇ . In addition, the differential expression during brain development suggest different roles for the TR variants during development 14"16 .
  • the mechanism of T 3 action via its receptor is quite complex due to the presence of multiple TRs 17"20 .
  • the TR ⁇ locus encodes in addition to the TR ⁇ gene another receptor denoted as Rev- ⁇ . Rev- ⁇ arises by transcription of the opposite strand of TR ⁇ gene and overlaps the ⁇ 2 region at the 3' end (Fig. B).
  • TR ⁇ 2 and TR ⁇ 3 variants the protein sequence of the latter is identical to that of TR ⁇ 2 with the exception that it lacks the first 42 amino acids of the carboxy terminus (Fig. C).
  • thyroid hormone receptors the actions of thyroid hormones can be ascribed in hypo- and hyperthyroidism. If the individual functions in hormone action of the receptors could be identified, agonists or agonists that are specific for either of the receptors could be used for treatment of specific target tissues without adversely affecting other tissues.
  • thyroid hormone function Treatment of many diseases associated with thyroid hormone function cannot be done today since administration of increased doses of the hormone to achieve a desired effect in a given tissue, leads to adverse effects in another.
  • the effects of thyroid hormones are mediated by two different receptors that are coexpressed in some tissues, whereas other tissues express only one of them. It should therefore be possible to design agonists and antagonists that are specific for each of the receptors and that can mediate a desired activation or repression of receptor function.
  • agonists and antagonists In order to allow testing of such components we have disrupted the TR ⁇ gene in the mouse genome, and bred such animals to homozygosity. These animals can grow to at least sexual maturity, and are therefore suitable tools for identifying the action of agonists and antagonists
  • a transgenic mammal which is heterozygous for an at least partially defective thyroid hormone receptor ⁇ gene.
  • the defective gene may be inactivated for example by an insertion, deletion, substitution or inversion or any other suitable genetic manipulation.
  • the mammal is a rodent, more preferably a mouse.
  • One heterozygous transgenic mammal in accordance with the invention may be bred with another such heterozygous transgenic mammal to produce a mammal which is homozygous for a defective thyroid hormone receptor ⁇ gene.
  • a transgenic mammal which is homozygous for an at least partially defective ⁇ thyroid hormone receptor ⁇ gene is provided.
  • the invention also provides cells derived from the animal of the invention which are heterozygous or homozygous for a defective thyroid hormone receptor ⁇ .
  • a method of producing a transgenic animal in accordance with the invention comprising : 1) preparing a gene encoding an at least partially defective thyroid hormone receptor ⁇ as described above;
  • the method may involve using cells or tissues derived from the transgenic
  • the transgenic mammal of the invention is suitable for testing the effects of agonists and antagonists of thyroid hormone action, in particular those that discriminate between TR ⁇ and
  • transgenic mammal of the invention or cells or tissues derived
  • thyroid hormone antagonists or agonists for treatment of e.g hypercholesterolemia or other diseases must therefore include a test for their influence
  • Such tissues include the hypophysis (producing growth hormone, prolactin, thyroid stimulating hormone, luteinizing hormone), the hypothalamus (thyrotropin releasing hormone, oxytocin), peripheral tissues (insulin growth factor I).
  • hypophysis producing growth hormone, prolactin, thyroid stimulating hormone, luteinizing hormone
  • hypothalamus thyrotropin releasing hormone, oxytocin
  • peripheral tissues insulin growth factor I.
  • thyroid hormone antagonists or agonists on such endocrine systems can be determined with the mammals of the present invention.
  • Basal metabolic rate, gluconeogenesis, lipogenesis, lipolysis and thermogenesis are
  • hormone antagonists or agonists on such endocrine systems can be determined with the transgenic mammal of the present invention.
  • TR ⁇ deficient mammals of the present invention allow the identification of such disease, symptoms, and their cure with suitable agonists.
  • Fig. 1 illustrates disruption of the TR ⁇ gene by homologous recombination
  • Fig. 2 illustrates an RT-PCR analysis of products of the wild type and mutant alleles of the TR ⁇ gene.
  • Fig. 1 A is a schematic representation of the TR ⁇ 1 protein showing the central DNA binding domain (filled in black) and C-terminal T3-binding domain.
  • Fig. IB top line illustrates the structure of the central region of the gene containing the first three coding exons that are common for both TR ⁇ 1 and TR ⁇ 2 (here numbered 3 to 5).
  • the middle line illustrates the targeting vector contained 3 kbp and 4 kbp respectively of 5' and 3' homologous flanking DNA and carried a 3 kbp deletion including part of exon number 3.
  • the bottom line shows the structure of the mutant allele generated by homologous
  • Figure IB contained from 5' to 3': a TK gene fragment from pMCI-HSV TK, a 3 kbp
  • TR ⁇ genomic DNA extending to a Kpn 1 site in the coding exon number 3, a neomycin resistance gene from pgkneobpA, a 4 kbp Xba-I-Hind in genomic fragment containing the TR ⁇ exons 4 and 5.
  • the construct was linearized at the 5' end of the TK gene
  • PMEFs primary mouse embryo fibroblasts
  • W9.5 cells were cultured in
  • Dulbecco's Modified Eagle medium (Specialty Media) supplemented with 15% defined fetal bovine serum (Hyclone), 1000 U/ml of recombinant LIF (Gibco), L-glutamine, non-essential amino acids, ⁇ -mercaptoethanol and antibodies as described 26 3 x 10 7 W9.5 cells at passage 12 were resuspended in 0.8 ml PBS containing 25 ⁇ g of linearized targeting vector DNA for
  • homologous recombination were expanded and stocks frozen.
  • the chromosome content of positive clones was determined by growth on microscope chamber slides for analysis in situ.
  • ES cells colonies were screened for homologous recombinants in pools of six. Cell pellets were lysed at 55°C overnight and DNA was prepared and digested overnight with Bam HI and Eag I, then analyzed on 0.7% agarose gels. DNA was transferred to Duralose-UV membrane
  • ES cells of recombinant clones were injected into C57B 1/6J blastocysts which were then transferred into pseudopregnant recipient female mice of strain C57BI76J.
  • Male chimaeric offspring were obtained with extensive ES cell contribution as judged by their agouti coat colour.
  • Five of these were bred with C57B1/6J female mice and produced agouti-coloured offspring indicating germline transmission. The genotype of these FI mice was determined and TRB heterozygotes were crossed to generate litters containing homozygous mutants. All
  • RT-PCR Reverse Transcriptase-Polymerase Chain Reaction
  • TRB mice was prepared and used to make first strand cDNA using as primer an antisense oligonuclcotide derived from the 3' terminal coding exon of the mouse TR ⁇ gene. RT-PCR analysis was then performed on the cDNA using the pairs of primers indicated in Figure 2 that
  • TR ⁇ 1 and TR ⁇ 2 specifically amplify products representing the N-terminal coding regions of the two TR ⁇ N- terminal variant proteins (TR ⁇ 1 and TR ⁇ 2) that are encoded by the TR ⁇ gene.
  • TR ⁇ 1 and TR ⁇ 2 specifically amplify products representing the N-terminal coding regions of the two TR ⁇ N- terminal variant proteins (TR ⁇ 1 and TR ⁇ 2) that are encoded by the TR ⁇ gene.
  • TR ⁇ 1 and TR ⁇ 2 specifically amplify products representing the N-terminal coding regions of the two TR ⁇ N- terminal variant proteins (TR ⁇ 1 and TR ⁇ 2) that are encoded by the TR ⁇ gene.
  • RT-PCR products of RNA from different tissues from wild type (+/+), heterozygous (-/+) and homozygous mutant (-/-) mice were generated using pairs of primers that specifically amplify products derived from TR ⁇ 1 and TR ⁇ 2, as indicated in the lower part of the figure.
  • mice both had ABR thresholds in the normal range, whereas Thrb " ' " mice
  • mice displayed significantly elevated thresholds that were often in the 70-100 dB range, indicating severe impairment. Indeed, 10-15% of Thrb ';" mice were profoundly deaf since no response could be evoked with any frequency tested at 100 dB, the upper limit of the apparatus. In mutants in which a response could be evoked, albeit with elevated thresholds, the resultant
  • mice at 2-3 weeks of age when hearing normally approaches adult sensitivity levels also demonstrated impairment in Thrb " ' " mice (p «0.01) compared to controls. This confirmed that the mutation caused a permanent failure of development of
  • mice produced as described above were viable, they displayed normal growth rates and
  • mice organs, with the exception of the thyroid gland which was variably enlarged in Thrb " ' " mice.
  • mice analysed at 5, 18 and 40 weeks of age The condition was not progressive since the pathology was not more pronounced, with no evidence of hyperplasia, in 40 week old mice.
  • mice Thyroid size increased in all genotypes with age, but there was no significant difference in the ratio of colloid:epithelium between Thrb " ' " and normal mice.
  • the thyroid glands of Thrb " ' " mice at postnatal day 7 also displayed an increase in the numbers and size of colloid-containing follicles indicating that the condition arose at an early age.
  • mice The observed thyroid pathology of the Thrb " ' " mice suggested that there could be abnormalities
  • TT4 total thyroxine
  • Thrb " ' " mice at 5 - 40 weeks of age irrespective of gender.
  • Fig. 4A shows that mean TT4 levels were elevated -2.5 fold in a representative analysis of 10 week old mice (means ⁇ SEM for Thrb " ' “ , Thrb " ' + were 11.5 ⁇ 1.07, 4.6 ⁇ 0.3, 4.1 ⁇ 0.3 ⁇ g/dL, respectively). Parallel increases
  • Thrb + + mice This confirmed the predicted thyroid hyperactivity and excluded abnormal serum binding or transport of T4 as the cause of the elevated serum hormone levels.
  • mice in Thrb " ' " mice.
  • the levels of total T3 were somewhat variable regardless of the genotype, perhaps indicating variability in the peripheral conversion of T4 to T3 in this mouse strain. However, free T3 levels were consistently elevated.
  • TSH was paradoxically elevated in Thrb " '
  • TSH ⁇ and TSH ⁇ subunits were elevated 2.5 and 3.3-fold respectively compared to Thrb +/+ mice, suggesting that the increased TSH levels in mice lacking Tr ⁇ reflected abnormal
  • mice revealed no abnormalities and immunohistochemical analysis showed no
  • mice resulted from defective thyrotrope function rather than from hyperplasia malformation of the pituitary gland.
  • mice were assessed using a range of behavioural tests. These analyses were valid since mice, like humans or rats, are susceptible to behavioural defects associated with congenital thyroid disorders and similar tests have demonstrated learning
  • mice of both genotypes spent equivalent time and activity in the quadrant where the platform had been located. Context fear conditioning and responses
  • mice revealed no obvious abnormalities in brain anatomy, including

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides a transgenic mammal which is heterozygous or homozygous for an at least partially defective thyroid hormone receptor β gene, cells derived from the mammal and methods for the use of the mammal and the cells.

Description

TRANSGENIC ANIMALS HAVING A DEFECTIVE THYROID HORMONE RECEPTOR BETA GENE
This application relates to transgenic animals, particularly mice, and tissues and cell lines
thereof that in a homozygous form lack the gene for thyroid hormone receptor β (TRβ). The
mice, tissues and cell lines of the invention may be used in the testing for pharmaceutical or clinical purposes of substances such as thyroid hormones T3 and T4 and possible antagonists
and agonists thereof.
The thyroid hormones tri-iodothyronine (T3) and thyroxine (T4) have a very wide range of effects. In adult mammals they influence nearly all organs, the metabolism of nutrients, basal metabolic rate and oxygen consumption. In humans, the deficiency or excess of circulating thyroid hormones results in the well characterised syndromes hypo- and hyperthyroidism.
The thyroid hormones are essential for the normal development of the central nervous system
particularly in the foetal and neonatal stages '"6. Deficiencies in the action of thyroid hormones lead to hypothyroidism that can be due to either acquired or congenital disorders. Some of the congenital causes of hypothyroidism are embryopathies as absence, hypoplasia,
or ectopic localization of the thyroid gland; enzymatic disorders; deficient hormone synthesis
and receptor disorders (Generalized Thyroid Hormone Syndrome (GRTS)). Unless treated, congenital hypothyroidism leads to irreversible mental retardation and short stature (dwarfism). Other symptoms include neurological dysfunctions such as poor coordination and balance, abnormal fine motor movements, speech problems, spasticity, tremor and hyperactive
1 deep tendon reflexes. In addition basal metabolic rate, gluconeogenesis, lipogenesis and cardiac output are decreased. Hypothyroidism in adults leads to symptoms similar to those described above, except for the mental retardation. However, adult patients are easily treated
with hormone therapy.
In contrast to congenital hypothyroidism, hyperthyroidism is more common in adults. In general, the symptoms are the reverse: increased metabolism, lower serum cholesterol levels, hyperactivity and tachycardia are hallmarks of elevated T3/T4 levels 25.
Thyroid hormones act through thyroid hormone receptors (TRs) which belong to the
superfamily of steroid hormone receptors. TRs are ligand dependent transcription factors which regulate the transcription of their target genes through responsive elements in the DNA.
In vertebrates there are a variety of TRs7"13 (Fig. A) derived from TRα and TRβ genes, which
are located at the 17th and 3rd chromosomes respectively in humans. There is considerable homology between the TRα and TRβ proteins and between the receptors in different species, such as rat, mouse, and human. The α-gene encodes the subtypes l and α2. The α2 subtype is not a functional receptor in the sense that it lacks T3/T4 hormone binding capability.
The β-gene encodes the subtypes β 1 and β2. The latter has so far been identified only at the
messenger RNA level. The physiological significance of these different proteins has not yet
been clarified. Different amino- and carboxy-termini for the TR variants suggest different trans-activating properties for TRα and Trβ. In addition, the differential expression during brain development suggest different roles for the TR variants during development 14"16. The mechanism of T3 action via its receptor is quite complex due to the presence of multiple TRs 17"20. The TRα locus encodes in addition to the TRα gene another receptor denoted as Rev-α. Rev-α arises by transcription of the opposite strand of TRα gene and overlaps the α2 region at the 3' end (Fig. B). Furthermore, there are TRα2 and TRα3 variants; the protein sequence of the latter is identical to that of TRα 2 with the exception that it lacks the first 42 amino acids of the carboxy terminus (Fig. C).
In humans, the GRTS has been related to TRβ gene disorders. No clinical syndromes have
yet been associated to TRα gene mutations suggesting that the TRα gene is either dispensable
or essential for life. It is equally unclear as to which of the two thyroid hormone receptors the actions of thyroid hormones can be ascribed in hypo- and hyperthyroidism. If the individual functions in hormone action of the receptors could be identified, agonists or agonists that are specific for either of the receptors could be used for treatment of specific target tissues without adversely affecting other tissues.
Treatment of many diseases associated with thyroid hormone function cannot be done today since administration of increased doses of the hormone to achieve a desired effect in a given tissue, leads to adverse effects in another. The effects of thyroid hormones are mediated by two different receptors that are coexpressed in some tissues, whereas other tissues express only one of them. It should therefore be possible to design agonists and antagonists that are specific for each of the receptors and that can mediate a desired activation or repression of receptor function. In order to allow testing of such components we have disrupted the TRβ gene in the mouse genome, and bred such animals to homozygosity. These animals can grow to at least sexual maturity, and are therefore suitable tools for identifying the action of agonists and antagonists
of TRβ.
According to one aspect of the invention there is provided a transgenic mammal which is heterozygous for an at least partially defective thyroid hormone receptor β gene. The defective gene may be inactivated for example by an insertion, deletion, substitution or inversion or any other suitable genetic manipulation.
Preferably, the mammal is a rodent, more preferably a mouse.
One heterozygous transgenic mammal in accordance with the invention may be bred with another such heterozygous transgenic mammal to produce a mammal which is homozygous for a defective thyroid hormone receptor β gene. Thus according to another aspect of the invention there is provided a transgenic mammal which is homozygous for an at least partially defective β thyroid hormone receptor β gene.
The invention also provides cells derived from the animal of the invention which are heterozygous or homozygous for a defective thyroid hormone receptor β.
According to another aspect of the invention there is provided a method of producing a transgenic animal in accordance with the invention the method comprising : 1) preparing a gene encoding an at least partially defective thyroid hormone receptor β as described above;
2) introducing that gene into suitable carrier cells;
3) inserting those carrier cells into an embryo; and
4) replacing the embryo into a mother, and allowing the embryo to develop to full term.
According to a further aspect of the invention there is provided a method of testing the
agonist/antagonist properties of a compound in relation to the thyroid hormone receptor, the
method comprising:
contacting a transgenic animal in accordance with the invention with the compound and
monitoring subsequent development of the animal.
Alternatively, the method may involve using cells or tissues derived from the transgenic
animal.
The transgenic mammal of the invention is suitable for testing the effects of agonists and antagonists of thyroid hormone action, in particular those that discriminate between TRα and
TRβ. In particular, the transgenic mammal of the invention or cells or tissues derived
therefrom can be used to study the following:
1. Administration of excess thyroid hormones decreases high serum cholesterol levels. However, an adverse side effect is that cardiac output also increases which can lead
to arrythmia. If these two functions of thyroid hormones are mediated by distinct receptors, a proper administration of receptor specific agonists or antagonists would lead to the desired decrease in serum cholesterol while leaving cardiac function
normal.
2. Hypo- and hyperthyroidism adversely affect bone structure. The use of receptor-
specific thyroid hormone antagonists or agonists for treatment of e.g hypercholesterolemia or other diseases must therefore include a test for their influence
on bone synthesis and turnover.
3. Regulation of heart functions such as pulse, arrythmia, or myocardiac muscle can be
targeted by the use of receptor specific thyroid hormone antagonists or agonists.
4. Many organs or tissues produce hormones in a thyroid hormone dependent manner.
Such tissues include the hypophysis (producing growth hormone, prolactin, thyroid stimulating hormone, luteinizing hormone), the hypothalamus (thyrotropin releasing hormone, oxytocin), peripheral tissues (insulin growth factor I). The effect of receptor
specific thyroid hormone antagonists or agonists on such endocrine systems can be determined with the mammals of the present invention.
5. Basal metabolic rate, gluconeogenesis, lipogenesis, lipolysis and thermogenesis are
increased in hyperthyroidism and decreased during hypothyroidism. The effect of
receptor specific thyroid hormone antagonists or agonists on such metabolic processes
can be determined with the mammal of the present invention. 6. Toxic effects of agonists and antagonists on normal and abnormal physiological metabolic processes.
7. Effects on brain or other neuronal function (hearing, peripheral nervous system), as
well as effects on embryonal and foetal development of receptor specific thyroid
hormone antagonists or agonists on such endocrine systems can be determined with the transgenic mammal of the present invention.
8. Effects on increasing or decreasing body growth in patients with growth disorders.
9. A large number of genes or gene products are known to be regulated by thyroid hormones. The effects of agonists and antagonists of such systems before clinical trials can commence.
10. Effect on haemopoiesis. Hypothyroid patients are usually anaemic.
11. Treatment of patients that have defective TRα receptor genes. As mentioned above, no patients with mutant TRα genes have been found, whereas genetic defects in more
than 250 patients with defective TRβ genes have been identified. The latter patients
were first clinically identified due to their inappropriate levels of thyroid hormones and other thyroid hormone regulated hormones such as TSH. It is therefore possible that diseases due to defects in the TRα gene have remained undetected because the patients have normal T3/T4 and TSH levels and their symptoms therefore would not be easily associated with a receptor dysfunction. The TRβ deficient mammals of the present invention allow the identification of such disease, symptoms, and their cure with suitable agonists.
Mammals in accordance with the invention and their production will now be described by way of example only with reference to the further accompanying drawings Figures 1-2 in which:
Fig. 1 illustrates disruption of the TRβ gene by homologous recombination; and
Fig. 2 illustrates an RT-PCR analysis of products of the wild type and mutant alleles of the TRβ gene.
Example 1
Generation of mutant mouse with deleted thyroid hormone receptor β gene.
EXPERIMENTAL PROCEDURES Targeting vector
A chick TRβ cDNA insert was used to screen a bacteriophage lambda library of genomic DNA of a 129sv strain mouse (Stratagene) to obtain overlapping clones that encompassed the entire coding domain of the TRβ gene. Fig. 1 A is a schematic representation of the TRβ 1 protein showing the central DNA binding domain (filled in black) and C-terminal T3-binding domain. Fig. IB top line, illustrates the structure of the central region of the gene containing the first three coding exons that are common for both TRβ 1 and TRβ 2 (here numbered 3 to 5). The middle line illustrates the targeting vector contained 3 kbp and 4 kbp respectively of 5' and 3' homologous flanking DNA and carried a 3 kbp deletion including part of exon number 3. The bottom line shows the structure of the mutant allele generated by homologous
recombination 5', nco and 3' probes used in Southern blot analyses are shown as well as the
band sizes predicted to be detected with the 3' probe following digestion with Barn HI and
Eag I: the wild type band size being 19 kbp whereas the mutant band is 10 kbp. Restriction
enzyme sites are indicated where relevant. X, Xba I; B, Bam HI; K, Kpn I; E, Eag I. The exon
structure was confirmed by DNA sequencing of plasmid sub-clones. The targeting vector
(Figure IB) contained from 5' to 3': a TK gene fragment from pMCI-HSV TK, a 3 kbp
fragment of TRβ genomic DNA extending to a Kpn 1 site in the coding exon number 3, a neomycin resistance gene from pgkneobpA, a 4 kbp Xba-I-Hind in genomic fragment containing the TRβ exons 4 and 5. The construct was linearized at the 5' end of the TK gene
by Bam HI digestion prior to electroporation.
Electroporation and selection of ES cells
W9.5 male ES cells derived from 129/sv mice were grown on feeder layers of G418-resistant
primary mouse embryo fibroblasts (PMEFs) in dishes that had been treated with 0.1% gelatin: PMEFs were mitotically inactivated by gamma-irradiation. W9.5 cells were cultured in
Dulbecco's Modified Eagle medium (Specialty Media) supplemented with 15% defined fetal bovine serum (Hyclone), 1000 U/ml of recombinant LIF (Gibco), L-glutamine, non-essential amino acids, β-mercaptoethanol and antibodies as described 26 3 x 107 W9.5 cells at passage 12 were resuspended in 0.8 ml PBS containing 25μg of linearized targeting vector DNA for
electroporation using a Bio-Rad Gene Pulser (500μF, 250V). Cells were then plated onto 60mm dishes. The next day the medium was replaced with medium containing 350 μg/ml G418 (dry weight, Gibco) and on day two, 2μM ganciclovir (a gift of Syntex Corp. Palo Alto,
CA) was added. The medium was replaced each day and on day 8, colonies were picked and
transferred into 48 well dishes. After 4-5 days growth in 48-well plates, each clone was
trypsinized and 9/10 of the suspension volume removed for DNA preparation. To the
remaining volume, fresh medium and PMEFs were added. Clones identified as positive for
homologous recombination were expanded and stocks frozen. The chromosome content of positive clones was determined by growth on microscope chamber slides for analysis in situ.
Southern blot hybridization analysis of ES cell clones and genotype determination
ES cells colonies were screened for homologous recombinants in pools of six. Cell pellets were lysed at 55°C overnight and DNA was prepared and digested overnight with Bam HI and Eag I, then analyzed on 0.7% agarose gels. DNA was transferred to Duralose-UV membrane
and hybridized using Quickhyb solution (Stratagene) with the indicated 3' probe (Figure 1).
Membranes were washed in O.lxSSC, 0.2% SDS at 62°C twice, then once at 65°C. DNA samples from mice were prepared from tail clips and genotypes routinely determined by digestion of 5-10 μg of DNA with Bam HI and Eag I and analysis by hybridization as
described above.
Blastocyst injection and mice breeding
ES cells of recombinant clones were injected into C57B 1/6J blastocysts which were then transferred into pseudopregnant recipient female mice of strain C57BI76J. Male chimaeric offspring were obtained with extensive ES cell contribution as judged by their agouti coat colour. Five of these were bred with C57B1/6J female mice and produced agouti-coloured offspring indicating germline transmission. The genotype of these FI mice was determined and TRB heterozygotes were crossed to generate litters containing homozygous mutants. All
analyses were performed with progeny obtained from crosses between these TRB
heterozygotes and thus represented hybrid mice derived from 129/sv (ES cell) and C57bl/6J
strains.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) analysis of mutant gene products
Total cellular RNA from selected tissues of wild type, heterozygous and homozygous mutant
TRB mice was prepared and used to make first strand cDNA using as primer an antisense oligonuclcotide derived from the 3' terminal coding exon of the mouse TRβ gene. RT-PCR analysis was then performed on the cDNA using the pairs of primers indicated in Figure 2 that
specifically amplify products representing the N-terminal coding regions of the two TRβ N- terminal variant proteins (TRβ 1 and TRβ 2) that are encoded by the TRβ gene. The products from mice of all three genotypes were purified and their DNA sequences were determined by
automated sequencer.
RT-PCR analysis of products of the wild type and mutant alleles
RT-PCR products of RNA from different tissues from wild type (+/+), heterozygous (-/+) and homozygous mutant (-/-) mice were generated using pairs of primers that specifically amplify products derived from TRβ 1 and TRβ 2, as indicated in the lower part of the figure. Products
were electrophoresed on 0.8% agarose gels and visualised by ethidium bromide staining. In
all tissues from homozygous mutant mice, the RT-PCR products were 100 bp shorter than in NOT TO BE TAKEN INTO CONSIDERATION FOR THE PURPOSES OF INTERNATIONAL PROCESSING
Example 2
Analysis of the effect of the thyroid hormone receptor β on the development of auditory function
Mice which were heterozygous (Thrb" +) were prepared as described above. The auditory-
evoked brainstem response (ABR) was tested in these mice. It was found that the threshold
sound pressure levels required for ABR were significantly elevated (p«0.01) for all pure
tones tested (8,16 and 32 kHz) and for a click stimulus in all adult Thrb"'" mice. Thrb" + and
control Thrb+/+ mice both had ABR thresholds in the normal range, whereas Thrb"'" mice
displayed significantly elevated thresholds that were often in the 70-100 dB range, indicating severe impairment. Indeed, 10-15% of Thrb';" mice were profoundly deaf since no response could be evoked with any frequency tested at 100 dB, the upper limit of the apparatus. In mutants in which a response could be evoked, albeit with elevated thresholds, the resultant
ABR waveforms were not significantly different from those of the controls, with normal peaks
and latencies, indicating that brainstem auditory functions were normal and suggesting a defect in the generation of the primary action potential from the cochlea. Since the
impairment was general with respect to all frequencies tested, the defect was not restricted to particular regions of the cochlea that are responsive to specific frequencies. There was not evidence for vestibular defects, since Thrb"'" mice showed no circling or other abnormal
behaviour. Analysis of mice at 2-3 weeks of age when hearing normally approaches adult sensitivity levels, also demonstrated impairment in Thrb"'" mice (p«0.01) compared to controls. This confirmed that the mutation caused a permanent failure of development of
auditory function. Example 3
Physiological effects of targeted interaction of the mouse Trβ gene.
Thyroid pathology in homozygous mutants
Thrb"'" mice produced as described above were viable, they displayed normal growth rates and
weight gain and they were fertile. Necropsy failed to reveal gross abnormalities in most
organs, with the exception of the thyroid gland which was variably enlarged in Thrb"'" mice.
Quantitative image analysis of histological sections indicated that thyroid areas were 1.5-2.0
fold increased (P<0.05) in overall size in homozygotes (mean ± SEM in mm2, 0.58±0.09, n = 10) compared to heterozygous (0.35±0.04, n = 9) and wild type (0.39±0.04, n = 8) mice at 5 weeks of age. There was no significant difference between Thrb"'* and Thrb+ + mice. Higher
magnificent revealed a diffuse enlargement of Thrb"'" thyroid glands resulting from an increase in both the numbers and size of follicles. The colloid of follicles from Thrb"'" mice frequently
contained large phagocytic-like cells that were often multi-nucleated and other cellular debris that was probably derived from degenerating epithelial cells.
This pathology suggested that the Thrb"'" thyroid glands were in a hyperactive state with
increased epithelial cell turnover, indicating that the mutation caused a recessive hyperthyroid-
like condition. No difference was detected between the sexes and the enlargement persisted
in mice analysed at 5, 18 and 40 weeks of age. The condition was not progressive since the pathology was not more pronounced, with no evidence of hyperplasia, in 40 week old mice.
Image analysis of thyroid sections demonstrated an approximately constant ratio of areas of
colloid:epithelium in Thrb"'" (mean ± SEM, 1.02±0.08, n - 10). Thrb"'+ (0.86±0.1, n = 9) and Thrb+/+ (0.91 ±0.1, n - 8) mice. Thyroid size increased in all genotypes with age, but there was no significant difference in the ratio of colloid:epithelium between Thrb"'" and normal mice. The thyroid glands of Thrb"'" mice at postnatal day 7 also displayed an increase in the numbers and size of colloid-containing follicles indicating that the condition arose at an early age.
Hormonal disorder
The observed thyroid pathology of the Thrb"'" mice suggested that there could be abnormalities
in thyroid hormone levels. Analysis of serum thyroid hormones revealed that the levels of
total thyroxine (TT4), the major product of the thyroid gland, were significantly elevated in
Thrb"'" mice at 5 - 40 weeks of age, irrespective of gender. Fig. 4A shows that mean TT4 levels were elevated -2.5 fold in a representative analysis of 10 week old mice (means ±SEM for Thrb"'", Thrb"'+ were 11.5±1.07, 4.6±0.3, 4.1±0.3 μg/dL, respectively). Parallel increases
in free T4 were observed in Thrb"'" mice (1.7±0.18 ng/dL) compared to Thrb"'+ (0.6±0.05) and
Thrb + + (0.5±0.06) mice. This confirmed the predicted thyroid hyperactivity and excluded abnormal serum binding or transport of T4 as the cause of the elevated serum hormone levels. Preliminary data indicated that there was a general decrease of TT4 levels in older Thrb"'" mice (-1.5 years of age), suggesting that the hyperactivity was ameliorated with age. The levels of total and free T3, the main biologically active form of thyroid hormone, were also elevated
in Thrb"'" mice. The levels of total T3 were somewhat variable regardless of the genotype, perhaps indicating variability in the peripheral conversion of T4 to T3 in this mouse strain. However, free T3 levels were consistently elevated.
Failure to regulate thyroid stimulating hormone Elevation of thyroid hormone levels normally suppresses TSH production by the pituitary thyrotropes. However, the mean serum levels of TSH were significantly elevated in Thrb*'"
compared to Thrb"'+ or Thrb+/+ mice at 5-40 weeks of age, irrespective of gender. Thus,
despite the high levels of thyroid hormones, TSH was paradoxically elevated in Thrb"'"
mutants. Northern blot analysis of pituitary RNA showed that levels of mRNA encoding
TSHα and TSHβ subunits were elevated 2.5 and 3.3-fold respectively compared to Thrb+/+ mice, suggesting that the increased TSH levels in mice lacking Trβ reflected abnormal
regulation of TSH gene transcription. Histological examination of pituitary glands from
Thrb"'" mice revealed no abnormalities and immunohistochemical analysis showed no
abnormal pattern of cells straining positively for the TSH subunits (Fig. 4D-G). Thus, the
over-production of TSH detected in Thrb"'" mice resulted from defective thyrotrope function rather than from hyperplasia malformation of the pituitary gland.
Central nervous system (CNS) function and anatomy
The absence of, or excessive exposure to T3 during a critical embryonic and neonatal period
can impair brain development (Legrand, 1984). To investigate if the absence of Trβ and/or the associated increase in thyroid hormone levels caused neurological defects, the function of
the nervous system in Thrb"'" mice were assessed using a range of behavioural tests. These analyses were valid since mice, like humans or rats, are susceptible to behavioural defects associated with congenital thyroid disorders and similar tests have demonstrated learning
disabilities in the hypothyroid (hyt) mutant mouse (Anthony et al, 1993). In a stringent
version of the Morris water task, requiring the mice to locate a hidden platform to escape.
Thrb"'" and Thrb+/+ mice learned to escape equally well with repeated trials over nine days. When the platform was removed, mice of both genotypes spent equivalent time and activity in the quadrant where the platform had been located. Context fear conditioning and responses
to paired stimuli that may indicate attention deficits were not significantly different in Thrb*'" mice (data not shown). However, these studies may not be conclusive as they employ an
acoustic stimulus to which the mutants could not respond reliably due to defective auditory
function (Forrest et al, submitted). In other tests such as activity in an open field and Y-maze,
Thrb"'" and Thrb+/+ mice also behaved similarly. Histological and histochemical analysis of
the CNS of Thrb"'" mice revealed no obvious abnormalities in brain anatomy, including
structures known to be sensitive to T3, such as the cerebellum hippocampus. Furthermore,
analysis of hippocampal field potentials did not indicate defects in long term potentiation. In conclusion, while development delays and attention deficits were not excluded, no overt neurological defects were detected in adult Thrb"'" mutants, suggesting that Trβ has subtle
rather than major functions in neurodevelopment.
REFERENCES
1) Schwartz HL (1983) In Oppenheimer. JH and Sammuels, HH (eds) Molecular Basis of Thyroid Hormone Action. Academic Press, New York 413.
2) Legrand, J (1984) In Yanai J (ed) Neurobehavioural Teraology. Elsevier Amsterdam 331-363.
3) Dussault, JH and Ruel J (1987) Annu. Rev. Physiol. 49 321-334.
4) McCarrison, R ( 1908) Lancet, 1275- 1280.
5) Gesell A, Amatruda CS and Culotta CS (1936) American J Diseases Children 52, 1117-1138.
6) Smith DW, Blizzard RM and Wilkins L (1957) Pediatrics 9, 1011-1022.
7) Thompson CC, Weinberger C, Lebo R and Evans R (1987) Science 237, 1610-1614.
8) Benbrook D and Pfahl M (1987) Science 238, 788-791. 9) Izumo S and Mahdavi V (1988) Nature 334, 539-542.
10) Koenig RJ, Warne RL, Brent GA, Harney JW, Larsen PR and Moore DD ( 1988) Proc. Natl. Acad. Sci. USA 85 5031-35.
11) Murray MB, Zilz ND, McCreary NL, MacDonald MJ and Towle, HC (1988) J. Biol. Chem 263 12770-12777.
12) Forrest D, Sjoberg M and Vennstrom B (1990) EMBO J 9, 1519-1528.
13) Yaoita Y, Shi Y-B and Brown DD (1990) Pro. Natl. Acad. Sci. USA 87 7090-7094.
14) Bradley DJ, Young m WS and Weinberger, C (1989) Proc. Natl. Acad Sci. USA 86 7250-7254.
15) Strait KA, Scwartz HL, Perez-Castillo A and Oppenheimer, JH ( 1990) J. Biol. Chem. 265 10514-10521.
16) Forrest D, Hallbook F, Persson H, and Vennstrom B (1991) EMBO J 10, 269-275.
17) Hodin RA, Lazar MA, Wintman BI, Darling DS, Koenig RJ, Moore DD and Chin WW (1989) Science 244, 76-79.
18) Lazar MA, Hodin RA, Darling DS and Chin WW (1988) Mol. Endocrinol 2, 893-901.
19) Lazar MA, Hodin RA, Darling DS and Chin WW (1989) Mol. Cell Biol. 9, 1128- 1136.
20) Miyajima N, Horiuchi R, Shibuya Y, Fukushige S, Matsubara K, Toyoshima K, Yamamoto T (1989) Cell 57, 31-39.
21) Thomas KR and Capecchi MR (1987) Cell 51, 503-512.
22) Mansour, SL, Thomas KR and Capecchi MR (1988) Nature 336, 348-352.
23) Bradley A, Kaufman MH and Evans MJ (1984) Nature 309, 255-256.
24) Smith AG, Heath JK, Donaldson DD, Wong GG, Moreau A, Stahl M and Rogers D (1988) Nature 336, 688-690.
25) Larsen R, Inbar S ( 1992) The Thyroid gland in " Wiliams Textbook of Endocrinology" 8th edition Eds Wilson J and Foster D. WB Saunders Company, Philadelphia.
26) Forrest D, Yuzaki M., Soares H.D, Ng L, Luk D.C, Sheng M, Stewart C. L, Morgan J. I, Connor J. A, and Curran T. Nearon 13 325-338 August 1994.

Claims

CLAIMS:
1. A transgenic mammal which is heterozygous or homozygous for an at least partially defective throid hormone receptor β gene.
2. A transgenic animal according to claim 1 in which the defective thyroid hormone
receptor β gene has been produced by an insertion, deletion, substitution or inversion
or other suitable genetic manipulation.
3. A transgenic animal according to claim 1 which is a rodent.
4. A transgenic animal according to claim 3 which is a mouse.
5. Cells derived from the transgenic mammal of claim 1 which are heterozygous or homozygous for defective throid hormone receptor β.
6. A method of producing a transgenic animal in accordance with claim 1, the method comprising the steps of:
1) preparing a gene encoding an at least partially defective thyroid hormone receptor β as described above;
2) introducing that thyroid hormone receptor β gene into suitable carrier cells;
3) inserting those carrier cells into an embryo; and 4) replacing the embryo into a mother, and allowing the embryo to develop to full term.
7. A method of testing the agonist/antagonist properties of a compound in relation to a thyroid hormone receptor, the method comprising the steps of: contacting a transgenic animal in accordance with claim 1 with the compound and monitoring the subsequent behavioural development of the animal.
8. A method of testing the agonist/antagonist properties of a compound in relation to a thyroid hormone receptor, the method comprising the steps of: contacting cells in accordance with claim 5 with the compound and subsequently monitoring the cells.
PCT/EP1996/001983 1995-05-11 1996-05-10 Transgenic animals having a defective thyroid hormone receptor beta gene WO1996035785A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU59981/96A AU5998196A (en) 1995-05-11 1996-05-10 Transgenic animals having a defective thyroid hormone recept or beta gene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43739095A 1995-05-11 1995-05-11
US08/437,390 1995-05-11

Publications (3)

Publication Number Publication Date
WO1996035785A2 true WO1996035785A2 (en) 1996-11-14
WO1996035785A3 WO1996035785A3 (en) 1996-12-12
WO1996035785A9 WO1996035785A9 (en) 1997-02-06

Family

ID=23736226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001983 WO1996035785A2 (en) 1995-05-11 1996-05-10 Transgenic animals having a defective thyroid hormone receptor beta gene

Country Status (2)

Country Link
AU (1) AU5998196A (en)
WO (1) WO1996035785A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095711A2 (en) * 2000-06-14 2001-12-20 Deltagen, Inc. Transgenic mice containing nuclear hormone receptor gene disruptions
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024282A1 (en) * 1993-04-09 1994-10-27 Pfizer Inc. A human t-cell receptor of the g-protein coupled receptor family

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024282A1 (en) * 1993-04-09 1994-10-27 Pfizer Inc. A human t-cell receptor of the g-protein coupled receptor family

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACTA MEDICA AUSTRIACA, vol. 21, no. 2, 1994, pages 56-60, XP002015494 CHATTERJEE, V.K.K.: "Resistance to thyroid hormone - an uncommon cause of thyroxine excess and inappropriate TSH secretion" *
CLINICAL RESEARCH MEETING, SAN DIEGO, CALIFORNIA, MAY 5-8, 1995, XP002015493 WONG, R. ET AL.: "A transgenic model of resistance to thyroid hormone (RTH): Correlation of mutant thyroid hormone beta receptor (TRbeta1) levels with the phenotype of fat loss and hyperactivity" & JOURNAL OF INVESTIGATIVE MEDECINE, vol. 43, no. Suppl.2, April 1995, page 223A WONG, R. ET AL.: "A transgenic model of resistance to thyroid hormone (RTH): correlation of mutant thyroid hormone beta (TRbeta1) levels with the phenotype of fat loss and hyperactivity" *
JOURNAL OF CLINICAL INVESTIGATION, vol. 88, December 1991, pages 2123-2130, XP000574480 PARILLA, R. ET AL.: "Characterization of seven novel mutations of the c-erbAbeta gene in unrelated kindreds with generalized thyroid hormone resistance" *
MOLECULAR ENDOCRINOLOGY, vol. 10, no. 1, 1996, pages 100-106, XP000603520 HAYASHI, Y. ET AL.: "A mouse model of resistance to thyroid hormone produced by somatic gene transfer of a mutant thyroid hormone receptor" *
MOLECULAR ENDOCRINOLOGY, vol. 4, no. 5, May 1990, pages 715-720, XP000603789 O'DONNELL, A. AND KOENIG, R.: "Mutational analysis identifies a new functional domain of the thyroid hormone receptor" *
MOLECULAR ENDOCRINOLOGY, vol. 8, no. 12, December 1994, pages 1605-1617, XP000603682 WOOD, W.M. ET AL.: "Structural and functional characterization of the genomic locus encoding the murine beta2 thyroid hormone receptor" *
MOLECULAR MEDICINE, vol. 1, no. 3, March 1995, pages 309-319, XP000603622 WONG, R. ET AL.: "Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone beta1 receptors" *
THE EMBO JOURNAL, vol. 15, no. 12, 17 June 1996, pages 3006-3015, XP000604851 FORREST, D. ET AL.: "Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095711A2 (en) * 2000-06-14 2001-12-20 Deltagen, Inc. Transgenic mice containing nuclear hormone receptor gene disruptions
WO2001095711A3 (en) * 2000-06-14 2002-09-26 Deltagen Inc Transgenic mice containing nuclear hormone receptor gene disruptions
WO2005085865A2 (en) * 2004-03-09 2005-09-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)
WO2005085865A3 (en) * 2004-03-09 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with thyroid hormone receptor beta (thrb)

Also Published As

Publication number Publication date
WO1996035785A3 (en) 1996-12-12
AU5998196A (en) 1996-11-29

Similar Documents

Publication Publication Date Title
Abel et al. Divergent roles for thyroid hormone receptor β isoforms in the endocrine axis and auditory system
Forrest et al. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue‐specific modulation of receptor function.
Balthasar et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis
Lahoud et al. Gene targeting of Desrt, a novel ARID class DNA-binding protein, causes growth retardation and abnormal development of reproductive organs
Ivanov et al. Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene
Iskandar et al. PDK-1/FoxO1 pathway in POMC neurons regulates Pomc expression and food intake
US7592314B2 (en) Use of VEGF and homologues to treat neuron disorders
US5698766A (en) Transgenic animal model for testing drugs for treating eating disorders and epilepsy
EP3505190A1 (en) Method for building model of animal suffering from non-human mammal obesity or related disease and use thereof
JP2002509736A (en) Mice deficient in corticotropin-releasing factor receptor-1
EP1554382B1 (en) Gpr54 knock-out mammals and screening methods using them
US20030009777A1 (en) Galanin
Maddox et al. An ENU-induced mutation in the Mertk gene (Mertknmf12) leads to a slow form of retinal degeneration
WO1996035785A2 (en) Transgenic animals having a defective thyroid hormone receptor beta gene
WO1996035785A9 (en) Transgenic animals having a defective thyroid hormone receptor beta gene
US20020104107A1 (en) Point mutant mice with hypersensitive alpha 4 nicotinic receptors: dompaminergic pathology and increased anxiety
US5817912A (en) Transgenic mice with disrupted NPY Y1 receptor genes
JP4550530B2 (en) Synaptic maturation disorder animal model
Abe et al. A mouse model system to study peroxisomal roles in neurodegeneration of peroxisome biogenesis disorders
US20090233840A1 (en) Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes
US20030041341A1 (en) Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1
US20110138488A1 (en) Deficiency in the histone demethylase jhdm2a results in impaired energy expenditure and obesity
WO2006096648A2 (en) Mouse model
AU2003238794A1 (en) Tr2, tr4, tr2/tr4 double knockouts and uses thereof
JP3471739B2 (en) Screening method for preventive / therapeutic agent for diseases caused by α1ECa2 + channel dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3,DRAWINGS,REPLACED BY NEW PAGES 1/4-4/4

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA